Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5616910 | 0.94 | MEN1 (0.47) | MEN1KMT2ATLR7NPSR1TDP1 | |
| SCHEMBL5616939 | 0.93 | MEN1 (0.46) | MEN1KMT2ATLR7NPSR1TDP1 | |
| SCHEMBL5616906 | 0.90 | NPSR1 (0.44) | MEN1KMT2ANPSR1TDP1SMN1; SMN2 | |
| SCHEMBL5616913 | 0.85 | NPSR1 (0.42) | MEN1KMT2ATLR7NPSR1TDP1 | |
| SCHEMBL5617019 | 0.84 | TLR7 (0.60) | MEN1KMT2ATLR7 | |
| SCHEMBL5617265 | 0.84 | GAA (0.48) | MEN1KMT2ANPSR1TDP1SMN1; SMN2 | |
| SCHEMBL5617028 | 0.84 | HPGD (0.45) | MEN1KMT2ANPSR1TDP1SMN1; SMN2 | |
| SCHEMBL5617245 | 0.83 | HPGD (0.47) | TLR7NPSR1TDP1SMN1; SMN2KDM4E | |
| SCHEMBL5617029 | 0.80 | LMNA (0.41) | MEN1KMT2ATLR7NPSR1TDP1 | |
| SCHEMBL5616941 | 0.80 | TLR7 (0.46) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697873-B2 | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| EP-1730143-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094531-A2 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219196-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | IL2, IL4, IFNG | MEN1 3874/4885KMT2A 2054/4885TLR7 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.